Literature DB >> 33559375

The cerebellum could serve as a potential imaging biomarker of dementia conversion in patients with amyloid-negative amnestic mild cognitive impairment.

Hyung-Ji Kim1, E-Nae Cheong2, Sungyang Jo1, Sunju Lee1, Woo-Hyun Shim3,4, Miseon Kwon1, Jae Seung Kim5, Bum Joon Kim1, Jae-Hong Lee1.   

Abstract

BACKGROUND AND
PURPOSE: As part of network-specific neurodegeneration, changes in cerebellar gray matter (GM) volume and impaired cerebello-cerebral functional networks have been reported in Alzheimer disease (AD). Compared with healthy controls, a volume loss in the cerebellum has been observed in patients with continuum of AD. However, little is known about the anatomical or functional changes in patients with clinical AD but no brain amyloidosis. We aimed to identify the relationship between cerebellar volume and dementia conversion of amyloid-negative mild cognitive impairment (MCI).
METHODS: This study was a retrospective cohort study of patients over the age 50 years with amyloid-negative amnestic MCI who visited the memory clinic of Asan Medical Center with no less than a 36-month follow-up period. All subjects underwent detailed neuropsychological tests, 3 T brain magnetic resonance imaging scans including three-dimensional T1 imaging, and fluorine-18[F18 ]-florbetaben amyloid positron emission tomography scans. A spatially unbiased atlas template of the cerebellum and brainstem was used for analyzing cerebellar GM volume.
RESULTS: During the 36 months of follow-up, 39 of 107 (36.4%) patients converted to dementia from amnestic MCI. The converter group had more severe impairments in all visual memory tasks. In terms of volumetric analysis, reduced crus I/II volume adjusted with total intracranial volume, and age was observed in the converter group.
CONCLUSIONS: Significant cerebellar GM atrophy involving the bilateral crus I/II may be a novel imaging biomarker for predicting dementia progression in amyloid-negative amnestic MCI patients.
© 2021 European Academy of Neurology.

Entities:  

Keywords:  Alzheimer disease; amyloid; cerebellum; florbetaben; mild cognitive impairment

Year:  2021        PMID: 33559375     DOI: 10.1111/ene.14770

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  3 in total

1.  Magnetic Resonance T1w/T2w Ratio in the Putamen and Cerebellum as a Marker of Cognitive Impairment in MSA: a Longitudinal Study.

Authors:  Sofia Cuoco; Sara Ponticorvo; Rossella Bisogno; Renzo Manara; Fabrizio Esposito; Gianfranco Di Salle; Francesco Di Salle; Marianna Amboni; Roberto Erro; Marina Picillo; Paolo Barone; Maria Teresa Pellecchia
Journal:  Cerebellum       Date:  2022-08-19       Impact factor: 3.648

Review 2.  Don't forget the little brain: A framework for incorporating the cerebellum into the understanding of cognitive aging.

Authors:  Jessica A Bernard
Journal:  Neurosci Biobehav Rev       Date:  2022-03-26       Impact factor: 9.052

3.  The impact of subthreshold levels of amyloid deposition on conversion to dementia in patients with amyloid-negative amnestic mild cognitive impairment.

Authors:  Hyung-Ji Kim; Jungsu S Oh; Jae-Sung Lim; Sunju Lee; Sungyang Jo; E-Nae Chung; Woo-Hyun Shim; Minyoung Oh; Jae Seung Kim; Jee Hoon Roh; Jae-Hong Lee
Journal:  Alzheimers Res Ther       Date:  2022-07-11       Impact factor: 8.823

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.